Search Results for “antibody” – Page 67 – media

Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).
- Source: pharmatimes
- 781
- February 24, 2018
angioedema HAE Market Views
Flu breath– sick people can spread the flu virus just by breathing

The flu is a bit of a stealth microbe. Infected people may shed significant amounts of flu virus simply by breathing, scientists have discovered.
- Source: cbc
- 584
- February 23, 2018
flu Researches
GSK delivers improvements in sales, margins and cash flow in 2017

GSK delivers improvements in sales, margins and cash flow in 2017：Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
- Source: GSK
- 494
- February 15, 2018
Company Insight GSK
Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.
- Source: Biospace
- 657
- February 11, 2018
Clinical Trial inhibitor mRCC Tecentriq
EMA accepts MAA for romosozumab in the treatment of osteoporosis

The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
- Source: europeanpharmaceuticalreview
- 884
- February 2, 2018
Amgen EMA Evenity (romosozumab) osteoporosis romosozumab
Russian researchers develop test strip to diagnose heart attack

Scientists at the National University of Science and Technology (NUST) MISIS in Russia have developed a new membrane test strip for quantitative immune chromatography rapid tests to rapidly and accurately detect an acute myocardial infarction by analysing blood for the presence of disease markers.
- Source: medicaldevice-network
- 540
- January 31, 2018
immune chromatography rapid test Researches
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMS) (BMY) under the license and collaboration agreement between the companies established in 2015. The milestone was triggered by initiation of a multi-arm Phase 2 clinical trial (NCT03336216), sponsored by Bristol-Myers Squibb Company, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. “Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.” The Phase 2 trial is expected to enroll approximately 160 ...
- Source: finance.yahoo
- 552
- January 31, 2018
Bristol-Myers Squibb cabiralizumab Opdivo
Seven medicines leap closer to EU approval

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
- Source: pharmatimes
- 994
- January 30, 2018
CHMP diabetes EMA haemophilia A Hemlibra polices Roche
Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, today announced the completion of a $58 million Series A financing. This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline. Polaris Partners, the founding investor that provided the initial seed funding, co-led the Series A financing along with Versant Ventures and Roche Venture Fund. SR One and BioInnovation Capital also participated in the round.
- Source: finance.yahoo
- 898
- January 22, 2018
antibody Company Insight immunomodulation
Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.
- Source: Prnewswire
- 747
- January 19, 2018
anti-cancer immune New Approvals RM-1929

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.